Introduction
in molecules potentially involved in effector cell targeting, that is, CD11b, lactadherin and CD9 molecules [7, 8] . These tumour-derived EXO isolated from malignant effusions can transfer tumour Ags to dendritic cells (DCs) and induce tumour-specific cytotoxic T lymphocyte (CTL) responses and antitumour immunity [9] [10] [11] . It has been reported that EXO need the host DC as an adjuvant for stimulation of CD8 ϩ CTL responses [12, 13] . Zitvogel et al. first demonstrated eradication of tumours by EXO vaccination in animal models [10] .
Subsequently, EXO-based vaccines have been confirmed to stimulate CD8
ϩ CTL responses and induce antitumour immunity [9, [14] [15] [16] [17, 18] . Heat shock protein (HSP) molecules are stress-induced molecular chaperones that function to facilitate presentation of endogenous antigenic peptides [19] 
. However, its efficiency is less effective because it only induces either prophylatic antitumour immunity in animal models or very weak antitumour immune responses in clinical trials

leading to potent adjuvant effect on stimulation of DC maturation and enhanced CD8
ϩ CTL responses [20] . Tumour-derived HSP have thus been used as adjuvant in cancer vaccines [21] .
It has been demonstrated that enhanced expression of cytoplasmic HSP in EXO derived from heat-shocked tumour cells induced more efficient CD8
ϩ CTL responses and antitumour immunity than EXO derived from untreated tumour cells [22, 23] [25] [26] [27] . [28] with pcDNAHSP70 vector expressing membrane-bound HSP70 and the control vector pcDNAneo without HSP70 expression, respectively [28] . We also incubated J558 tumour cells at 42ЊC for 1 
. It has also been shown that expression of membrane-bound exosomal HSP stimulated cytolytic activity of natural killer (NK) cells [24]. Within HSP family, HSP70, the peptides of which can be quickly loaded onto MHC I and II complexes of DCs, can exhibit potent adjuvant effect in stimulation of the host immune responses and antitumour immunity
In this study, we compared the efficiency of stimulation of T-cell responses and antitumour immunity between membrane-bound HSP70-expressing EXO derived from HSP70-engineered tumour cells engineered and cytoplasmic HSP70-expressing EXO derived from heat-shocked tumour cells. We first transfected a myeloma cell line J558 expressing its tumour Ag P1A
hr for heat shock treatment to generate heat-shocked J558 (J558HS) tumour cells. We then purified EXOHSP, EXOneo and EXOHS from transfected J558HSP and J558neo and heat-shocked J558HS cell culture supernatants, respectively. To assess the antitumour immunity derived from EXO vaccination, we immunized wild-type BALB/c mice with membrane-bound HSP70-expressing EXOHSP or control EXOneo or cytoplasmic HSP70-expressing EXOHS. We demonstrate that EXOHSP vaccination is able to more efficiently induce DC maturation leading to stimulation of type 1 helper CD4 ϩ T (Th1) and more efficient CD8 ϩ T-cell responses and immunity against J558 tumour cells than EXPHS and EXOneo vaccination. We also elucidate that the antitumour immunity resulted from EXOHSP vaccination is mediated by both CD8
ϩ CTL and NK cells. 
Materials and methods
Reagents, cell lines and animals
Tumour cell lysate preparation
Live J558 tumour cell lysates were prepared as previously described [32] . 
Flow cytometric analysis of tumour cells and tumour cell-released EXO
Tumour cells and tumour cell-derived EXO were analysed by flow cytometry as previously described [13, 33] 
Stimulation of immature DCs
The generation of bone marrow derived immature DCs from wild-type BALB/c mice in presence of GM-CSF (1 ng/ml) has been previously described [34] . [35] .
Cytotoxicity assay
The in vivo cytotoxicity assay was performed as previously described [35] . C57BL/6 splenocytes were harvested from naive mouse spleens and incubated with either high (3. [39] . [22, 23] . As shown in Fig. 1(B Fig. 3C , DCs with uptake of EXOHSP (DC ϩ EXOHSP) stimulated the strongest allogeneic T-cell proliferation
Results
Phenotypical characterization of engineered and heat-shocked J558 tumour cells
Fig. 1 Phenotypic analysis of J558HSP-released EXO. (A) J558HSP, J558HS and J558 tumour cells were stained with a panel of Abs (solid lines) or isotype-matched irrelevant Abs (dotted lines), and analysed by flow cytometry. (B) J558HSP, J558HS and J558 tumour cells as well as irradiated J558 tumour cells were stained with FITC-annexin V (solid lines) or FITC anti-rat IgG (dotted lines) and analysed by flow cytometry. (C) Electron micrograph of EXO. The image shows small cup-shaped vesicles of 60-100 nm in diameter, which are representative of EXO released by tumour cells. Bar, 100 nm. (D) Western blot analysis of tumour cell-released EXO and tumour cell lysates was performed with a panel of antibodies. (E) Flow cytometric analysis of EXO. EXO were grouped for analysis of expression of surface molecules. (F) EXOneo, EXOHS and EXOHSP released from J558neo, J558HS and J558HSP tumour cells were stained with a panel of FITC antibodies (solid lines) or isotype-matched irrelevant FITC antibodies (dotted lines), and analysed by flow cytometry. One representative experiment of two is displayed. than DCs with uptake of EXOneo (DC ϩ EXOneo) and EXOHS (DC ϩ EXOHS) (P Ͻ 0.05). We then assessed whether DCs with uptake of EXO by incubation of immature DCs with EXO for overnight induce P1A-specific antitumour immunity. As shown in Fig. 3(D), DCs with uptake of EXOneo (DC ϩ EXOneo), EXOHS (DC ϩ EXOHS) and EXOHSP (DC ϩ EXOHSP) were able to stimulate P1A-specific antitumour immunity to protect one of eight, three of eight and eight of eight mice from tumour growth after the immunized mice were challenged with J558 tumour cells, respectively, indicating that EXOHSP-treated DCs are the most immunogenic among these three types of DCs.
EXO HSP stimulate type 1 CD4 ؉ T-cell responses
To assess whether EXOHSP can stimulate CD4 ϩ T-cell responses, we performed in vitro T-cell proliferation assay by using CD4
ϩ Fig. 4(A [43] . As shown in Fig. 4(C Fig. 4(D [12, 50] . We have recently demonstrated 
T cells derived from EXO-immunized mouse spleens. As shown in
Fig. 3 J558HSP-released EXOHSP stimulate DC maturation. (A) Flow cytometric analysis of EXO-treated DCs. Immature DCs with or without incubation of EXOneo, EXOHS and EXOHSP were stained with a panel of antibodies (solid lines) or isotype-matched irrelevant antibodies (dotted lines), and analysed by flow cytometry. Mean fluorescence intensity of solid line / mean fluorescence intensity of dotted line was presented in each panel. (B) Cytokine secretion. Culture supernatants of DCs alone (DC), DC with EXOHS (DC ϩ EXOHS) and DC with EXOHSP (DC ϩ EXOHSP) were tested using cytokine ELISA kits. Values represent the mean of triplicates from three experiments. (C) Mixed T lymphocyte reaction assay. Irradiated DCs including DC ϩ EXOHS and DC ϩ EXOHSP and their two-fold dilutions were co-cultured in 96-well plates with a constant number of allogeneic C57BL/6 naïve T cells. After 3 days, T-cell proliferation was measured by adding 1 Ci
